This award is open to manufacturers or UK distributors of injectable products for the UK aesthetics market. Finalists will be chosen from products that support a wide range of indications and can show evidence of good safety and efficacy, optimum duration and tangible benefits over similar products on the market. This category is only open to products that have been available for a year or more. You are encouraged to keep your entry concise and clear; bullet points and the use of formatting options such as bold, underlines and italics are encouraged to ensure your entry is easy to digest for judges. A strict character limit of 1,700 (including spaces) is enforced for each question and you must not exceed this; however, your entry does not have to meet it. References are included in the character count, although you may supply a reference list as part of your supplementary materials if it exceeds the character count. The winner will be selected from the finalists using a combination of Aesthetics reader votes and judges’ scores. Voting will constitute a 30% share of the final score.
Within the UK facial aesthetics market, BOTOX® (botulinum toxin type A) is currently licensed for the temporary improvement in the appearance of: moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), moderate to severe lateral canthal lines (crow’s feet lines) seen at maximum smile, moderate to severe forehead lines at maximum eyebrow elevation - when the severity of the facial lines has an important psychological impact in adult patients.(1)
BOTOX® is a prescription-only medicine in the UK.(1), Including both aesthetics and therapeutics indications, BOTOX® has 35 approved indications globally,(2) including a range of disorders including depression, migraine, bladder overactivity, blepharospasm, tremor, cervical dystonia and multiple sclerosis (2) and is available in 97 countries worldwide. Ten of those indications currently approved in the UK.(2)
Profhilo® is a revolutionary BDDE-free, thermally stabilized hyaluronic acid product for skin remodelling produced by IBSA Italia with the patented NAHYCO™ technology.
Profhilo has proven to be much appreciated for its characteristics of safety, high spreadability and cohesivity. These qualities have been shown to be very effective in treating skin laxity in areas such as face, neck, décolletage, hands, arms, abdomen and knees.
Teosyal RHA is the first hyaluronic acid dermal filler specifically designed to work in synchronisation with patients’ facial expressions and provide a natural looking result whilst remaining undetectable.
The technology of Teosyal RHA has recently been credited, by receipt of FDA approval of RHA 2, 3 & 4 for moderate to severe dynamic wrinkles and folds. Teoxane are the first company to have three dermal filler products approved for FDA at one time, which reinforces Teoxane’s commitment to delivering science-based, high-quality and innovative HA products to the global market.
Teosyal RHA 1 is designed for fine lines and placed superficially in the barcodes, neck and décolleté. The highest of stretch of our RHA range, this product will stretch with our facial expressions and maintain performance under dynamic conditions.
Teosyal RHA 2 and RHA 3 are indicated to treat dynamic wrinkles, such as the forehead, glabella, nasolabial fold and marionette lines. Both with optimal strength and stretch capabilities, these products are perfect for natural rejuvenation in the mid to deep dermis. These products are also commonly used, and are indicated for, lip augmentation.
Teosyal RHA 4, is designed and indicated for volume replacement in extended and dynamic areas, such as the cheeks and contours of the face. Ideal for sculpting, Teosyal RHA 4 will result in a firm, more youthful appearance. The highest strength capacity of all our RHA range, this product will maintain volumising performance under the deep dermis.
The complete line of RRS® CE Class III sterile injectable medical products are designed to repair, refill and stimulate the skin, providing hydrobalance combined with biorevitalising benefits. RRS consists of 14 different products:
RRS® Hyalift 35, 75 and 75 Proactive are dermal implants for photo ageing, offering skin rejuvenation and hydrobalance with non-cross-linked HA.
RRS® HA Injectable is a dermal implant for skin laxity.
RRS® HA Tensor Lift is a dermal implant for skin photo ageing with a tensing effect. Similar to HA Injectable, but with the addition of 0.5% DMAE.
RRS® HA Whitening is a dermal implant for skin photo ageing with an anti-pigmentation effect.
RRS® Skin Relax is a dermal implant for photo ageing associated with excessive skin tension.
RRS® HA Eyes is a dermal implant for the area around the eyes for rejuvenation, fine lines & dark circles.
RRS® Silisorg is a dermal implant for the treatment of skin laxity. The ideal areas to treat include the neck, back, elbow and arms. Organic silicium and resveratrol build collagen and elastin.
RRS® Silisorg HA has the addition of non-crosslinked HA for delicate areas and to treat UV induced skin photoageing.
RRS® Silisorg Tensor contains 0.1% DMAE to improve laxity.
Body: RRS® solutions for tackling popular bodily concerns such as hair loss, cellulite and stretch marks:
RRS® HA Strimatrix is a dermal implant for the treatment of stretch marks.
RRS® HA Cellutrix is a dermal implant for the treatment of cellulite, stimulating microcirculation and improving the appearance of cellulite.
Hair - XL Hair is a dermal implant for alopecia, activating hair restoration by increasing proliferation of human papilla cells.
JUVÉDERM® VYCROSS is not a single product, but a comprehensive collection of hyaluronic acid (HA) facial fillers that are designed and tailored for the most treated areas of the face.(1) Each product can be selected and used in combination with each other to create bespoke treatment plans that suit patients’ needs. Because the collection has been designed in this way, each product carries its own unique positioning.(2–6)
Juvéderm® VOLITE – for when you want to enhance skin quality.(2) Designed to enhance skin quality attributes on the face, neck, décolletage and hands.(7)(8)
Juvéderm® VOLBELLA – for when you want to refine features and reduce fine lines (3), Used to treat any fine lines, enhance the lips and refine asymmetrical features.(3)
Juvéderm® VOLIFT – for when you want to fill lines and shape features4
For filling deep wrinkles and lines, and shaping the lips.(4)
Juvéderm® VOLUMA – for when you want to correct mid-face volume(5)(9)(10) Created to enhance and restore facial volume in the mid face (5)
Juvéderm® VOLUX – for when you want to define the lower face (6)(11)(12)
Designed to restore and create volume in the chin and jaw area. (6)
The JUVÉDERM® VYCROSS collection has continued to grow in size over the years. Juvéderm® VOLUX is the latest addition to the collection, having been launched at an international level in Q1 2019.
Ellansé is placed subdermal or onto periosteum for the replacement of facial volume, contours and definition. It has also successfully been used to rejuvenate the hands.
Another benefit of treatment with Ellansé is the improvement in skin quality as a result of the freshly generated Type 1 collagen and it has been successfully used to ameliorate atrophic scars and deep acne pits, this can be achieved through bio stimulation in the deep dermis leaving behind small micro droplets of product with a cannula.
Mr Nick Lowe and Dr Philippa Lowe recently published a paper relating to the use of Ellansé in the treatment of atrophic scars – “New treatments for Atrophic Scars”. In “A main treatment category for hollow, rolling atrophic scars is the use of dermal filler injections. An ideal filler category is one that can stimulate new dermal collagen under atrophic scars.” “Recently, collagen stimulation fillers such as Ellansé have replaced HA fillers and Sculptra for many atrophic scars and skin rejuvenation in our clinic.
The Ellansé IFU also states the product can be used for:
Ellanse gained its CE mark in 2009. It is currently going through FDA approval in the US.